Abstract: Described herein is a method of enriching lymphocytes from a biological sample, the method comprising: (a) removing large cells and small cells from the biological sample by a size based selection method to obtain lymphocytes, wherein the large cells comprise granulocytes or monocytes, or a combination thereof, and the small cells comprise platelets, red blood cells, or a combination thereof; (b) contacting the lymphocytes with an activating agent to obtain activated lymphocytes; and (c) removing inactivated lymphocytes from the activated lymphocytes using a sized based selection method to obtain activated enriched lymphocytes, thereby obtaining enriched activated lymphocytes.

Abstract: The present disclosure relates to use of an anti-IL-13R?1 antibody (such as eblasakimab) or a binding fragment thereof and pharmaceutical formulations comprising same to treat patients with atopic dermatitis (such as lesional atopic dermatitis) including a patient population that received prior treatment with dupilumab, for example to stimulate disease modification.

Abstract: An antibody, antigen binding fragment thereof and compositions comprising the same, which is an inhibitor of signalling through IL-13R?1, by binding the said receptor, for use in the treatment of allergic disease, such as atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) in a highly allergic patient where the baseline IgE levels have been established and are at a level of at least 10,000 KU/L+/?2,000.

Abstract: An antibody, antigen binding fragment thereof or a pharmaceutical formulation, which is an inhibitor of signalling through IL-13R?1 by binding said receptor and compositions comprising the same for use in the treatment of atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) by parenteral administration of a treatment cycle comprising a dose in the range 200 mg to 600 mg, (such as 400 to 600 mg), wherein the disease is modified by a percentage reduction in EASI score in the range ?20 to ?100% from the baseline.

Abstract: The present disclosure provides a method of treatment comprising inhibiting IL-13R with an antibody or binding fragment thereof specific for the receptor with a VH sequence of SEQ ID NO: 51 or a sequence at least 95% identical thereto, and VL sequence of SEQ ID NO: 53 or a sequence at least 95% identical thereto, wherein said antibody or binding fragment is administered at a dose in the range 600 mg to 900 mg at least once each month, in particular less than twice a month.

Abstract: The invention provides a method for the purification of cytochrome P450 molecules, the method comprising expressing in a host cell culture a cytochrome P450 molecule; recovering said cells from said culture and suspending said cells in a high salt buffer; lysing said cells and removing cell debris to provide a high-salt lysate; adding to said lysate a detergent to provide a high-salt-detergent lysate; and recovering said P450 from said lysate. The method provides yields of P450 proteins suitable for crystallization.

Abstract: The invention provides a method for the purification of cytochrome P450 molecules, the method comprising expressing in a host cell culture a cytochrome P450 molecule; recovering said cells from said culture and suspending said cells in a high salt buffer; lysing said cells and removing cell debris to provide a high-salt lysate; adding to said lysate a detergent to provide a high-salt-detergent lysate; and recovering said P450 from said lysate. The method provides yields of P450 proteins suitable for crystallization.